Potential COVID-19 antiviral formulated with siRNA-nanoparticles
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.
List view / Grid view
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.
A new study has shown that previous coronavirus infection may contribute to the immune response of patients infected with SARS-CoV-2.
A new cancer-killing virus called CF33 has shown success in pre-clinical trials, helping the immune system to eradicate tumours.
Small molecules named CS1 (bisantrene) and CS2 (brequinar) have been developed by researchers to suppress the growth of tumours and have shown promise in mouse models.
Combining the chlorotoxin peptide with conventional CAR structures, researchers have created a new CAR T cell therapy that has successfully combatted glioblastomas in mice.
New cell experiments show more effective genetic 'cuts' that could one day become the foundation of more effective gene therapies.
Scientists in the US have developed a promising new CAR T-cell therapy that targets the BAFF-R protein, which has demonstrated superior cancer destruction to existing FDA-approved CAR-T therapies.
The team found that astrocytes inhibit growth of precursor cells that become myelin, and speed up the neural network in the brain...